Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 18/20 | 0.60 |
| ▸ | RARB | P10826 | 18/20 | 0.60 |
| ▸ | RARG | P13631 | 18/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140748 | 0.89 | RARA (0.48) | RARARARBRARGCYP3A4 | |
| SCHEMBL6596743 | 0.89 | CYP3A4 (0.49) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6589951 | 0.88 | RARA (0.64) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL1140826 | 0.88 | RARB (0.60) | RARARARBRARGALDH1A1RXRA | |
| SCHEMBL6587152 | 0.88 | RARB (0.56) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL14384928 | 0.86 | RARB (0.53) | RARARARBRARGALDH1A1RXRA | |
| SCHEMBL13784637 | 0.86 | RARA (0.42) | RARARARBRARGALDH1A1 | |
| SCHEMBL6594145 | 0.85 | RARB (0.60) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6591582 | 0.85 | RARA (0.60) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL8330895 | 0.82 | RARA (0.39) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381183-A1 | TARGETING S100A9-ALDH1A1-RETINOIC ACID SIGNALING TO SUPPRESS BRAIN RELAPSE IN EGFR-MUTANT LUNG CANCER | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| WO-2023141659-A2 | TARGETING S100A9-ALDH1A1-RETINOIC ACID SIGNALING TO SUPPRESS BRAIN RELAPSE IN EGFR-MUTANT LUNG CANCER | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-07-27 | — | — | WO | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-2026778-A2 | USE OF A RAR ANTAGONIST OR INVERSE AGONIST FOR THE TREATMENT OF CHEMOTHERAPY AND/OR RADIATION THERAPY SIDE EFFECTS | Vitae Pharmaceuticals, Inc. (US) | 2009-02-25 | — | — | EP | claimed |
| US-20080214652-A1 | Methods of treating hyperlipidemia | ALLERGAN SALES, INC. | 2008-09-04 | — | — | US | claimed |
| EP-1392284-B1 | METHODS OF TREATING HYPERLIPIDEMIA | ALLERGAN INC (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007136653-A2 | USE OF A RAR ANTAGONIST OR INVERSE AGONIST FOR THE TREATMENT OF CHEMOTHERAPY AND/OR RADIATION THERAPY SIDE EFFECTS | VITAE PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| US-20050171151-A1 | Methods of treating hyperlipidemia | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| EP-1392284-A2 | METHODS OF TREATING HYPERLIPIDEMIA | Allergan, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| US-20020193403-A1 | Methods of treating hyperlipidemia | ALLERGAN SALES, INC. (US) | 2002-12-19 | — | — | US | claimed |
| WO-2002089781-A2 | METHODS OF TREATING HYPERLIPIDEMIA | ALLERGAN INC. (US) | 2002-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171151-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | RARA 37/4885RARB 40/4885RARG 32/4885 |
| US-20080214652-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | RARA 37/4885RARB 40/4885RARG 32/4885 |
| US-20020193403-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | RARA 37/4885RARB 40/4885RARG 32/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | RARA 964/4885RARB 1112/4885RARG 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.